AST 101
Alternative Names: AST-101Latest Information Update: 04 Dec 2023
At a glance
- Originator Aptamer Sciences
- Class Antihyperglycaemics; Drug conjugates
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 01 Dec 2023 Discontinued for Diabetes mellitus in South Korea (unspecified route) (Aptamer Sciences pipeline, December 2023)
- 28 Apr 2023 Aptamer Biosciences files for patent protection with for Insulin receptor aptamer and pharmaceutical composition in USA (Aptamer Sciences website, April 2023 )
- 20 Apr 2023 Early research in Diabetes mellitus in South Korea (unspecified route) (Aptamer Sciences pipeline, April 2023)